Mitral Valve Repair — Cost, Top Hospitals & Success Rates | MyMedicPlus

The mitral valve sits between the left atrium and left ventricle and controls the one-way flow of oxygenated blood through the left side of the heart. When the valve fails — either leaking (regurgitation) or narrowing (stenosis) — the heart must work harder, eventually leading to left ventricular dysfunction, atrial fibrillation, pulmonary hypertension, and heart failure.

Mitral valve repair reconstructs the native valve rather than replacing it with a mechanical or bioprosthetic substitute. Repair is the preferred strategy when technically feasible because it preserves left ventricular geometry and function, avoids lifelong anticoagulation (required with mechanical valves), and is associated with superior long-term survival compared with replacement.

A high-volume centre with a dedicated mitral team can achieve repair rates exceeding 95% for degenerative (myxomatous) disease. The procedure may be performed through a conventional median sternotomy, a right mini-thoracotomy (minimally invasive), or robotic-assisted endoscopic ports. For patients who are high surgical risk, transcatheter edge-to-edge repair (TEER) with the MitraClip or PASCAL device is an established alternative.

Mitral valve repair addresses a spectrum of structural and functional valve abnormalities:

• Degenerative mitral regurgitation (MR) — the most common indication; caused by leaflet prolapse or flail leaflet from myxomatous degeneration (Barlow's disease) or fibroelastic deficiency; typically affects the posterior leaflet P2 segment
• Functional (secondary) MR — valve leaflets are structurally normal but tethered or restricted due to left ventricular dilation in dilated or ischaemic cardiomyopathy; annuloplasty ring insertion corrects the annular dilation
• Ruptured chordae tendineae — sudden-onset severe MR following spontaneous chordal rupture or infective endocarditis; often requires emergency repair
• Mitral valve prolapse (MVP) — billowing of one or both leaflets into the left atrium during systole; repair is indicated when significant MR develops
• Rheumatic mitral stenosis — commissurotomy (splitting fused commissures) is feasible for pliable, non-calcified valves; now largely addressed by percutaneous mitral balloon commissurotomy (PMBC)
• Infective endocarditis — repair during active infection is possible at experienced centres when anatomically suitable

Current ACC/AHA guidelines (2021) and ESC guidelines (2021) recommend repair based on symptoms, left ventricular function, and anatomical complexity:

• Class I (recommended) — symptomatic severe MR with LVEF >30%; asymptomatic severe MR with LVEF ≤60% or LVESD ≥40 mm; MR with new-onset atrial fibrillation or resting pulmonary artery pressure >50 mmHg; repair at a Heart Valve Centre of Excellence when durability is expected to exceed 95%
• Class IIa (reasonable) — asymptomatic severe MR with progressive LV enlargement; repair when LVEF is >60% and LVESD is 40–44 mm with low surgical risk
• TEER (transcatheter) criteria — severe symptomatic degenerative or functional MR, anatomically suitable valve (EVEREST criteria), and prohibitive or high surgical risk (STS score >8%)
• Contraindications to repair — severely calcified annulus, commissural fusion not amenable to repair, low repair probability (complex bileaflet disease), or patient preference for valve replacement

The choice of approach is guided by surgeon expertise, patient anatomy, frailty, and institutional volume:

• Conventional open mitral valve repair (median sternotomy) — full sternotomy with cardiopulmonary bypass (CPB) and cardioplegic arrest; optimal exposure for complex bileaflet disease; gold-standard for repair durability assessment
• Minimally invasive mitral valve repair (right mini-thoracotomy) — 5–6 cm right anterior thoracotomy with peripheral CPB cannulation; 2–3 day shorter hospital stay, less blood loss, faster return to activity; comparable repair rates to open surgery at experienced centres
• Robotic-assisted mitral valve repair — endoscopic ports with robotic arms (da Vinci system); enhanced visualisation and dexterity; longest learning curve; offered at select high-volume centres; meta-analyses show comparable outcomes with less pain and faster recovery
• Transcatheter edge-to-edge repair (TEER) — MitraClip / PASCAL — percutaneous catheter via femoral vein, transseptal puncture; clip(s) approximate the free edges of the mitral leaflets creating a double-orifice valve; performed under echocardiographic and fluoroscopic guidance without CPB; preferred for high-risk surgical patients; reduces MR severity (rarely achieves 0 MR) but reduces hospitalisations and improves QoL
• Repair techniques used — regardless of approach, the operation may include: posterior leaflet resection (triangular or quadrangular), chordal transfer or neochord implantation (ePTFE sutures), anterior leaflet augmentation, commissuroplasty, and annuloplasty ring/band insertion (semi-rigid or flexible ring)

Extensive evidence supports a strong preference for repair when achievable:

• Superior survival — multiple studies and ACC/AHA guidelines document better 10- and 20-year survival after repair versus replacement for degenerative MR
• Preservation of left ventricular function — repair maintains native annular-papillary muscle continuity, which supports LV geometry and systolic function; replacement disrupts this relationship
• No lifelong anticoagulation — mechanical valve replacement requires INR-guided warfarin indefinitely, with associated bleeding and thromboembolic risks; repair does not
• No structural valve deterioration — bioprosthetic replacements degenerate and require re-intervention at 10–15 years; a successful repair typically lasts the patient's lifetime
• Lower early mortality — operative mortality for elective repair at a high-volume centre is 0.5–1%, lower than for replacement
• Lower rate of endocarditis — native valve repair carries lower lifetime risk of prosthetic valve endocarditis compared with any prosthesis

Mitral valve repair is a major cardiac operation with procedure-specific risks:

• Repair failure / conversion to replacement — intra-operative transoesophageal echocardiography (TOE) guides quality assessment; significant residual MR on TOE prompts immediate re-repair or conversion; occurs in 2–5% of cases even at expert centres
• Stroke — risk is 1–2%; embolic events arise from cardiac manipulation, air embolism, or atrial thrombus; anticoagulation bridges the early post-operative period
• Systolic anterior motion (SAM) of the mitral valve — a complication specific to repair causing LVOT obstruction; managed intra-operatively with ring size adjustment, leaflet augmentation, or volume loading
• Atrial fibrillation — new or persistent AF occurs in 20–40% after surgery; anticoagulation and rhythm management initiated accordingly
• Bleeding and re-exploration — occurs in 2–5%; risk increased with antiplatelet medications and reoperations
• Acute kidney injury — secondary to CPB; usually transient; dialysis required in <2% of elective cases
• Wound infection / mediastinitis — deep sternal wound infection in 0.5–1% after sternotomy; risk reduced with minimally invasive or robotic approaches
• Late recurrence of MR — freedom from reoperation at 10 years is 90–95% for degenerative MR repair at expert centres; functional MR repair has higher recurrence due to ongoing ventricular disease

Post-operative care is structured to monitor repair durability, manage rhythm, and support functional recovery:

• Intensive care unit — 1–2 days post-operatively for haemodynamic monitoring and ventilator weaning
• Hospital stay — 5–7 days for open / minimally invasive repair; 2–3 days after TEER
• Pain management — intercostal nerve blocks or epidural analgesia reduce opioid use after mini-thoracotomy; sternal precautions (no pushing/pulling >2 kg) for 6–8 weeks after sternotomy
• Anticoagulation — short-term anticoagulation (warfarin or NOAC) for 3 months is recommended by many centres after repair; indefinite anticoagulation if AF is present
• Cardiac rehabilitation — structured exercise programme beginning at 4–6 weeks significantly improves functional capacity and quality of life
• Echocardiographic surveillance — transthoracic echocardiogram (TTE) at discharge, 1 month, 6 months, 12 months, and then annually to assess repair durability and LV function
• Return to driving and work — driving typically at 4–6 weeks (after sternotomy); sedentary work at 4–6 weeks; physical labour at 8–12 weeks
• Endocarditis prophylaxis — dental and invasive procedures require antibiotic prophylaxis for 6 months post-operatively and indefinitely if a prosthetic ring remains

Mitral valve repair is a resource-intensive cardiac procedure; costs vary substantially:

• Surgical approach — robotic surgery commands the highest fees (robot equipment and consumables); conventional open surgery is typically less expensive than robotic or minimally invasive at the same centre
• TEER device cost — MitraClip and PASCAL systems cost $20,000–$30,000 per case (device alone), which narrows the total cost difference versus surgery in high-risk patients
• Hospital tier and country — India offers repair at JCI-accredited centres for $5,000–$10,000 (all-inclusive); Singapore $18,000–$30,000; Thailand $12,000–$22,000; USA $60,000–$120,000+; UK (private) £25,000–£45,000
• Intensive care and HDU stay duration — early extubation and fast-track protocols reduce ICU costs significantly
• Surgeon and team volume — high-volume mitral teams achieve lower complication rates, which reduce downstream hospitalisation costs and re-intervention rates
• Annuloplasty ring type — rigid, semi-rigid, and flexible rings vary in cost; some surgeons use suture-based posterior band annuloplasty at lower cost for selected cases

When repair is not feasible or preferred, or when surgery carries prohibitive risk, alternatives include:

• Mitral valve replacement (MVR) — mechanical valve (lifelong warfarin; excellent durability) or bioprosthetic valve (no warfarin for sinus rhythm patients; re-intervention at 10–15 years); chosen when repair is not durable or anatomy is unsuitable
• Transcatheter mitral valve replacement (TMVR) — emerging technology implanting a valve prosthesis inside the native mitral valve via catheter; indications evolving; particularly useful for valve-in-ring or valve-in-MAC settings
• Transcatheter edge-to-edge repair (TEER) — MitraClip or PASCAL for high-risk surgical patients with degenerative or functional MR
• Percutaneous mitral balloon commissurotomy (PMBC) — for rheumatic mitral stenosis with pliable non-calcified valves; catheter-based dilation avoids surgery; first-line for suitable anatomy
• Optimised medical therapy — for patients declining surgery or with functional MR; includes ACE inhibitors/ARBs/sacubitril-valsartan, beta-blockers, diuretics, and CRT-D for eligible patients; addresses LV remodelling but does not correct the valve